Risk Materials

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

Keytruda (Pembrolizumab): Patient Alert Card

The provision of this card to patients is required by the terms of the Marketing Authorisation. Please ensure that you carry this card with you at all times and that you have read and understood this information as it contains important safety information that you need to be aware of before, during and after treatment with pembrolizumab

Keytruda (pembrolizumab): Information for Patients Brochure: Important safety information to minimise the risk of immune-related adverse reactions

As part of the terms of the Marketing Authorisation for Keytruda, MSD are required to provide patients with information to help minimise the risk of immune-related adverse reactions that may occur with treatment with pembrolizumab. Please ensure that you have read and understood this information as it contains important safety information that you need to be aware of before, during and after treatment with pembrolizumab.

Keytruda- explanatory note to RMM

The attached note describes the updates to the Patient Alert Card and the Patient Information Brochure.

Send us feedback

If you would like to make a comment or send us feedback on this material, click here.